Application status and progress of biomarkers for ductal carcinoma in situ
ZHANG Yonghui
CAO Xuchen
Abstract：Although there is a broad consensus that ductal carcinoma in situ( DCIS) of the breast is the precursor lesions of infiltrated breast carcinoma( IBC) . The understanding of the biology and clinical behavior of DCIS is currently inadequate. Invasive breast cancer is a fatal disease, while DCIS is an indolent disease. In order to guide individualized clinical treatment, the focus is on the prediction of the risk of progression from DCIS to IBC and the risk of local recurrence after breast conserving surgery. Biomarkers have guided the clinical work and predicted different risk of IBC in recent years, but their application in DCIS is worthy of further in?vestigation. This review highlights the biomarkers in DCIS and its role of risk prediction.
Keywords：Ductal carcinoma in situ( DCIS)BiomarkersRecurrencePrognosis
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 455-459 )